The PI3K/AKT/mTOR signaling pathway is an effective therapeutic target in PTEN-deficient cancer cells, but its inhibitors can induce resistance via feedback activation of STAT3, which provides an empirical basis for combining both PI3K/AKT/mTOR and STAT3 inhibitors. This evidence concerns the gene MTOR and cancer.